GLP1R and type 2 diabetes mellitus: Published reports have also demonstrated that treatment with exenatide, a GLP-1 receptor agonist, suppresses the plasma concentration and production rate of Apo B-48, but not of Apo B-100, in healthy humans [26] and DPP-4 inhibitors such as vildagliptin, sitagliptin, and alogliptin lower Apo B-48 concentrations in patients with type 2 diabetes [10, 11, 27, 28].